tumor mutational burden
Marengo Therapeutics Advancing Bispecific Antibody to Phase II After Positive First-in-Human Data
Premium
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
ROME Trial Shows Benefit of Tumor-Agnostic Targeted Therapy Guided by a Molecular Tumor Board
Premium
Patients on therapies recommended by an MTB had better progression-free survival and overall response rates than those on standard-of-care therapy.
Association for Molecular Pathology Releases New Tumor Mutational Burden Testing Recommendations
The joint consensus guideline, authored by AMP, ASCO, CAP, and SITC, seeks to establish evidence-based standards for validation and reporting of TMB tests in the clinic.
The data presented at ASCO's annual meeting are promising, experts said, but will need longer follow-up to prove there is a benefit for patients.